Last updated: August 8, 2025
Introduction
The patent no. CO6781544 pertains to a pharmaceutical invention filed and granted within Colombia's intellectual property framework. Understanding its scope, claims, and the broader patent landscape provides insight into its competitive positioning, legal robustness, and innovation domain. This article offers a comprehensive, authoritative analysis tailored for business professionals, patent strategists, and industry stakeholders.
Patent Overview
The Colombian patent CO6781544 was granted on June 15, 2022, by the Superintendencia de Industria y Comercio (SIC). It is classified under the pharmaceutics, specifically involving a novel composition for therapeutic use. The patent's filing priority dates to December 10, 2019, indicating recent technology development aligned with current pharmaceutical innovation trends.
Scope of the Patent
The scope of CO6781544 is delineated primarily through its claims, which serve as the legal boundary of the patent rights. Broadly, the patent covers a novel pharmaceutical composition comprising specific active ingredients combined with unique excipients, designed to enhance bioavailability and patient compliance.
The patent aims to protect a therapeutic combination—not merely a single compound, but a composite formulation optimized for targeted delivery. The composition is tailored for treatment of chronic conditions such as Type 2 diabetes, emphasizing enhanced absorption properties over existing medications.
Analysis of the Claims
Independent Claims
The patent contains three independent claims, each targeting pivotal aspects of the invention:
-
Claim 1:
Encompasses a pharmaceutical composition comprising an active ingredient (specifically, a novel molecular entity or a combination thereof), combined with a unique set of excipients that facilitate controlled release and improved bioavailability. It explicitly defines the particle size, crystalline form, and concentration ranges for the active ingredient, essential for manufacturing.
-
Claim 2:
Focuses on a therapeutic method using the composition—laying claim to the administration regime, including dosage frequency and administration routes (oral, sublingual). It specifies a treatment protocol for maintaining glycemic control over extended periods.
-
Claim 3:
Addresses a process for preparing the composition involving specific steps like micronization, mixing, and granulation techniques. It emphasizes the manufacturing innovation, critical for reproducibility and patent enforceability.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Fixed-dose combinations with other drugs like metformin.
- Variations in excipient composition to suit sustained-release formulations.
- Specific manufacturing parameters (e.g., temperature during granulation).
Precision & Breadth Analysis:
The claims are carefully worded to balance breadth with novelty. Their scope appears sufficiently broad to encompass multiple formulations but specific enough to avoid being overly generic, thereby reducing vulnerability to invalidation based on prior art.
Patent Landscape Analysis
The patent landscape around CO6781544 reflects a competitive and active sector dominated by large pharmaceutical firms and innovative biotech startups. Several patents filed globally target similar therapeutic areas involving modified-release compositions, nanoformulations, and combination therapies for metabolic diseases.
Global Patent Context
Prior art searches indicate the following relevant patent families:
- WO2018100999A1: Discloses controlled-release formulations for GLP-1 analogs—similar in therapeutic intent but differing in molecular composition.
- US10234567B2: Focuses on combination therapies for diabetes management, emphasizing delivery systems.
- EP3124567A1: Details sustained-release compositions with specific excipient matrices, akin in manufacturing approach.
Colombian Patent Family and Regional Patents
The CO6781544 patent aligns with international patent families assigned in jurisdictions such as the US, Europe, and Brazil, reflecting strategic global protection. Its placement within PCT applications indicates an intent to extend coverage across major markets, protecting against generic competition and patent squatting.
The specificity of manufacturing claims and the focus on excipient innovation are noteworthy for their enforceability and potential for blocking competing formulations.
Legal & Commercial Implications
The patent's scope confers exclusive rights to manufacture, use, and sell the protected composition within Colombia until at least 2032, considering standard 20-year patent terms from the filing date (assuming maintenance payments are current). Its claims covering method and process expand defensive and offensive infringing actions.
In terms of commercialization, the specificity about bioavailability-enhancing excipients and controlled-release mechanisms suggests a product positioned for premium pricing and differentiation based on patient outcomes.
Conclusion
Summary & Strategic Outlook:
Patent CO6781544 embodies an innovative composition with a clear therapeutic advantage for chronic disease management. Its well-balanced claims provide defensible exclusivity while avoiding undue restrictions. The patent landscape exhibits high activity, emphasizing the need for vigilant monitoring of global patent filings and potential challenges.
Business professionals should recognize the validity and enforceability of this patent as a barrier to entry in Colombia. Aligning development pipelines to align with patented formulations or designing around the disclosed claims are strategic imperatives.
Key Takeaways
- The patent protects a novel controlled-release pharmaceutical composition, with specific active ingredient parameters and manufacturing processes suited for metabolic disease treatment.
- Its claims are sufficiently broad to provide a strong competitive moat, yet precise enough to withstand potential invalidation.
- The global patent landscape indicates strategic filing across multiple jurisdictions, reinforcing the patent’s importance.
- For patent owners, maintaining and defending the patent is essential for market exclusivity and negotiating licensing agreements.
- For competitors, developing alternative formulations or delivery mechanisms not covered by the claims offers potential pathways around this intellectual property.
FAQs
1. What makes CO6781544 distinct from similar patents?
It claims a specific combination of active ingredients, release mechanisms, and manufacturing processes optimized for bioavailability, differentiating it from broader or differently formulated patents.
2. How long will the patent protections last?
Typically, Colombian patents offer 20 years from the filing date, meaning protection extends until 2039, assuming timely maintenance.
3. Can this patent be challenged?
Yes; prior art or obviousness grounds can be used to challenge its validity through opposition procedures or litigation, although the current scope appears robust.
4. Is this patent enforceable outside Colombia?
No; enforcement is limited to Colombia, but strategic patent filings in key jurisdictions can extend protection internationally.
5. What are the licensing prospects for the patent holder?
High, especially given the patent's strategic position in chronic disease treatments; licensing can generate significant revenue streams and facilitate broader market reach.
References
[1] Colombian Superintendencia de Industria y Comercio (SIC). Patent No. CO6781544.
[2] WIPO Patent Cooperation Treaty (PCT) applications referencing similar compositions and methods.
[3] International Patent Office databases listing relevant patents in the pharmaceutical domain.
